UBS AM
INFI

UBS AM’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

UBS AM’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-22,299
Closed -$35K – 2704
2016
Q3 		$35K Hold
22,299
– – ﹤0.01% 2592
2016
Q2 		$30K Hold
22,299
– – ﹤0.01% 2605
2016
Q1 		$118K Sell
22,299
-820
-4% -$5.02K ﹤0.01% 2547
2015
Q4 		$181K Sell
23,119
-2,000
-8% -$17.2K ﹤0.01% 2560
2015
Q3 		$212K Hold
25,119
– – ﹤0.01% 2465
2015
Q2 		$275K Buy
25,119
+2,000
+9% +$25.7K ﹤0.01% 2417
2015
Q1 		$323K Buy
23,119
+1,000
+5% +$15.3K ﹤0.01% 2215
2014
Q4 		$374K Buy
22,119
+2,400
+12% +$34.9K ﹤0.01% 2093
2014
Q3 		$265K Hold
19,719
– – ﹤0.01% 2219
2014
Q2 		$251K Sell
19,719
-273,006
-93% -$2.84M ﹤0.01% 2288
2014
Q1 		$3.48M Sell
292,725
-43,494
-13% -$584K ﹤0.01% 1135
2013
Q4 		$4.64M Buy
336,219
+8,600
+3% +$121K 0.01% 1022
2013
Q3 		$5.72M Buy
327,619
+90,900
+38% +$1.74M 0.01% 945
2013
Q2 		$3.85M Buy
+236,719
New +$7.33M 0.01% 1025

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's INFI Position: Q4 2016 in Review

UBS AM sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2016, closing a stake of 22,299 shares — an estimated $35K sold.

UBS AM first reported a position in INFI in Q2 2013 and held it in 14 quarters. The position peaked at $5.72M in Q3 2013. 94 funds tracked by Wall St. Rank hold INFI as of Q4 2016.

  • UBS AM reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • UBS AM sold 22,299 Infinity Pharmaceuticals, Inc. shares in Q4 2016, an estimated $35K.
  • UBS AM first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 14 quarters.
  • UBS AM's Infinity Pharmaceuticals, Inc. position peaked at $5.72M in Q3 2013.
  • 94 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2016.

Based on UBS AM's 13F filing for Q4 2016, filed 14 Feb 2017.